Better Health for All

Alkermes' core business delivers exceptional health benefits by developing and commercializing FDA-approved medicines for serious mental illness and addiction, including schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and multiple sclerosis. In 2024, over 210,000 people were treated with their products, and there is no evidence of harmful products.

The company maintains an outstanding safety record, with all FDA inspections classified as “No Action Indicated” for the past 5 years, and 2024 lost time and recordable injury rates (0.06 and 0.4 respectively) significantly below industry benchmarks. Mental health and addiction mitigation are central to Alkermes' mission. The company offers FDA-approved treatments for alcohol and opioid dependence, including relapse prevention, and supports extensive community recovery programs. Alkermes was awarded a Platinum Bell Seal for Workplace Mental Health in 2024 and sponsors non-profits like NAMI and MHA, funding numerous mental health programs through its Inspiration Grants (over $5 million since 2016). Alkermes demonstrates industry-leading risk transparency through a Code of Conduct requiring full and fair disclosure, balanced promotional communications, an ISO-certified Risk Management System, and a public Early Access Policy. The company also exhibits comprehensive ethical frameworks for clinical trials, adhering to Good Clinical Practices, ensuring informed consent, patient safety, data integrity, and privacy. Healthcare education initiatives are comprehensive, targeting employees, healthcare professionals, and the public through sponsorships and grants. Furthermore, Alkermes has shown patent flexibility by granting licenses for generic versions of VIVITROL in the U.S. starting in 2027. While Alkermes offers patient assistance programs and targets vulnerable populations through grants, specific quantitative data (e.g., percentages of revenue, R&D, or population reach) required by the rubric to assign higher tiers is not provided for price accessibility, vulnerable reach, health innovation investment, health equity programs, healthcare workforce support, preventative health measures, and global health crisis response, resulting in a neutral score for these KPIs. The company is actively designing a new wastewater treatment system in Ohio to mitigate moderate health externalities from active pharmaceutical ingredients.

Fair Pay & Worker Respect

The CEO to median employee pay ratio for 2024 was 45:1

, with CEO Richard F. Pops' compensation at $10,151,430 and median employee compensation at $225,915 . Employee reviews from 2020-2024 indicate an overall rating of 3.7 out of 5 stars and a culture rating of 3.6 out of 5 stars . Positive comments were noted regarding salary, benefits, work environment, supportive teams, and excellent PTO/benefits . However, concerns were also raised about high expectations, lack of tolerance for errors, management support, nepotism, and lack of inclusivity . No regulatory actions, violations, fines, or compliance issues related to labor law or human rights have been mentioned in the provided articles. The company has stated a commitment to closing gender pay gaps but has not provided specific quantitative data on pay equity .

Honest & Fair Business

Alkermes maintains a clean regulatory record, with all FDA inspections of its facilities in the past five years classified as "No Action Indicated."

The company has a publicly available Code of Business Conduct and Ethics, requiring fair and honest dealings from employees, officers, and directors. This code includes a toll-free hotline for anonymous reporting of suspicious activity, and employees making good-faith reports are protected from retaliation. All new employees receive training on the Comprehensive Compliance Program, including the Code, with routine refresher and update training. Suppliers are also expected to report violations. Alkermes implemented an Incentive Compensation Recoupment Policy, effective October 2, 2023, which is triggered by an accounting restatement due to material noncompliance with financial reporting requirements, regardless of fault. In the past five years, Alkermes had two financial restatements: an amendment to its 2022 Annual Report on April 26, 2023, and an amendment to its 2021 Annual Report on April 29, 2022. The company is subject to and expects its suppliers to comply with major anti-bribery and anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, the UK Anti-Bribery Act, the Irish Criminal Justice (Corruption Offences) Act 2018, and the Anti-Kickback Statute. Its Code of Business Conduct and Ethics sets specific limits on gifts to medical professionals ($100 per gift, $2,500 per HCP per year in some states) and a meal cap ($130 per meal). The company's compliance program includes oversight by the Legal department under the Chief Compliance Officer, training, monitoring, and auditing authority for operating functions. Independent verification of ethical claims and compliance includes periodic assessments of the company's Information Security Management System by third-party assessors, and inspections of facilities by the FDA, EMA, and other global regulatory agencies. The company also audits contract manufacturers and suppliers.

Kind to Animals

Alkermes conducts animal testing for its research and development programs, with no products certified cruelty-free and no information provided on the use of non-animal testing methods or the volume of animals used.

The company is committed to the ethical and responsible treatment of research animals, adhering to defined practices and standards monitored by an Institutional Animal Care and Use Committee (IACUC). All animal research complies with applicable local, national, and international laws, including the National Research Council’s Guide for the Care and Use of Laboratory Animals. Alkermes contractually requires its Contract Research Organizations, academic institutions, and animal vendors to adhere to these same standards. All third-party vendors directly involved in the development, manufacture, or packaging of proprietary medicines are assessed through on-site audits and/or tabletop reviews, and Quality personnel audit all contract manufacturers and GxP suppliers for compliance. The company does not publicly engage in animal welfare policy improvement. For wildlife conservation, Alkermes developed a plan in 2022 to convert 12 acres of grassland at its Ohio facility into a pollinator field. They planted 25 unique species of plants in this space to increase site biodiversity, which are expected to become full grown by 2026. Employees also participate in local conservation efforts such as beach cleaning and clearing walking trails.

No War, No Weapons

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its core business activities do not involve arms manufacturing, military contracts, or conflict facilitation. Consequently, the company has no revenue from arms or defense contracts, does not develop dual-use technologies, and has no sales to embargoed regimes related to military goods.

There is no defense business to oversee, no exports requiring military-specific certification, and no defense-related lobbying. The company does not engage in defense procurement, operate in conflict regions requiring specific human rights due diligence, or fall under the Arms Trade Treaty. Its ethical red lines and compliance programs focus on general human rights and labor practices, not weapons-related issues. There is no exposure to controversial weapons, no war-risk audits are required, and no conflict-linked partners are identified. The company also does not have mineral inputs that would require conflict minerals certification, nor does it procure from conflict zones. Therefore, all KPIs related to the 'No War, No Weapons' value are not applicable to Alkermes' operations.

Planet-Friendly Business

Alkermes plc reported combined Scope 1 and Scope 2 greenhouse gas emissions of 46,320.264 metric tons of CO2 equivalent in 2023, representing a 5.85% decrease from 2022.

However, the company has not published a category-level breakdown of its Scope 3 emissions. In 2024, 90% of total waste generated was diverted from landfill, with 72% recycled and 18% processed in waste-to-energy facilities. The company maintains an exemplary environmental compliance history, with no non-compliances noted during a January 2020 inspection and all regulatory inspections completed successfully to date. , Alkermes has a Task Force on Climate-Related Financial Disclosure (TCFD) Statement and considers climate-related scenarios that may impact operations, though specific pathways are not detailed. The company has not mentioned SBTi-validated, science-based carbon reduction targets. Regarding renewable energy, the Ohio facility procured 30% of its electricity from renewable sources in 2024, and the Athlone business (prior to its sale in May 2024) used 100% certified renewable electricity. In 2022, Alkermes conducted a full-site survey at its Ohio facility and developed a plan to convert 12 acres of planted grassland into a pollinator field, expected to be full grown by 2026. , Alkermes partners with EcoVadis to evaluate over 100 key suppliers on ESG metrics, including climate change mitigation and adaptation.

Respect for Cultures & Communities

Alkermes states a commitment to corporate responsibility, encompassing community impact and respect for human rights

. The company highlights support for research, education, patient advocacy, and community development initiatives , and mentions partnerships, sponsorships, corporate memberships, and charitable giving . Alkermes also has an Inspiration Grants program that funds community-based programs addressing unmet needs related to addiction, serious mental illness, and cancer . However, the provided articles do not contain specific quantitative data or detailed qualitative evidence for any of the defined KPIs related to Respect for Cultures & Communities, such as the number of formal partnerships with indigenous groups, percentage of revenue reinvested locally, or details on cultural impact assessment protocols.

Safe & Smart Tech

Alkermes has reported no material information security incidents as of February 2025 and February 2026

, and states it has not sold personal information in the preceding 12 months. The company's Information Security Management System (ISMS) is aligned with the ISO/IEC27001:2022 international standard. Alkermes maintains a global data privacy compliance program designed to meet GDPR, HIPAA, and CCPA requirements , and FDA inspections of its sites over the past five years have resulted in “No Action Indicated” classifications. The company believes it is in material compliance with the California Health & Safety Code sec. 119402. Users are afforded rights under GDPR and CCPA, including access, rectification, erasure, restriction, objection, data portability, and the ability to withdraw consent and unsubscribe from emails. Alkermes conducts periodic security audits, vulnerability assessments, and penetration testing. The company provides extensive, regular, and role-specific security training for all employees, with compliance monitored by electronic learning systems , but no effectiveness metrics are provided. Data is retained only for periods reasonably necessary to fulfill stated purposes , without specific retention periods or collection limits detailed.

Zero Waste & Sustainable Products

Alkermes demonstrates strong waste diversion, with 97% of total waste generated in 2022 either recycled (90%) or processed in waste-to-energy facilities (7%).

In 2023, this rate was 95%. and in 2024, it was 93%. The company implements comprehensive waste management plans across all facilities. Specific waste reduction initiatives include a 75% reduction of waste shipments in Massachusetts lab areas in 2023 , diverting approximately 19.7 tonnes of waste from landfill in Ohio cafeterias in 2023 by using compostable materials , and recycling 69 kgs of plastic from R&D labs in Massachusetts in 2024. Alkermes also shifted from incineration to fuel blending for some waste streams and is designing a new wastewater treatment system in Ohio. For hazardous waste, 98% was either recycled or processed in waste-to-energy facilities in 2024 , with 97% in 2022 and 2023. While no hazardous waste was sent to landfill in 2020 , small quantities (9.5kg in 2023 , 18kg in 2024 ) were sent from Ohio and Massachusetts facilities, handled in accordance with regulations. No waste disposal violations were reported between 2020 and 2024. Alkermes assesses opportunities for circularity and enhanced its internal green chemistry strategy in 2024 , forming a dedicated team for green and sustainable processes in drug substance manufacturing. The company improved material efficiency by eliminating several hazardous reagents and solvents in the production of an active pharmaceutical ingredient. Alkermes plans to refresh baseline performance data and establish sustainability and emissions goals , but specific waste reduction targets with timelines are not yet publicly available. The company has comprehensive supplier waste requirements, informing strategic partners of EHSS standards and expectations. By the end of 2024, 90% of proprietary product CMOs, key raw materials, and critical operations suppliers were evaluated through the EcoVadis platform , and a new Supplier Code of Conduct was adopted in 2024.